Therapeutic Drug Monitoring of Risankizumab in Psoriasis Patients (BIOLOPTIM-RIS)

NCT05685940 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Psoriasis Vulgaris

Interventions

PROCEDURE: Venapuncture
PROCEDURE: Patient questionnaires

Sponsor

University Hospital, Ghent